TB-500 Fragment 17-23 (sequence: LKKTETQ) represents the minimal actin-binding domain of Thymosin Beta-4. This 7-amino-acid fragment retains the ability to sequester G-actin and promote cell migration and wound healing.
Category: Healing / Research. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only
Sequesters G-actin monomers, promoting actin polymerization and cytoskeletal reorganization. This drives cell migration, angiogenesis, and wound healing at the cellular level.
Safety considerations: No specific safety data for this fragment.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | Prohibited in sport (WADA) |
The fragment contains the key actin-binding domain, but the full peptide may have additional activities from other domains. No head-to-head studies exist.
TB-500 Fragment 17-23 (sequence: LKKTETQ) represents the minimal actin-binding domain of Thymosin Beta-4. This 7-amino-acid fragment retains the ability to sequester G-actin and promote cell migration and wound healing.
On the PeptideAtlas A–F scale, TB-500 Fragment 17-23 is rated D (Preclinical Only). Mostly animal or preclinical evidence
Research-only
Sequesters G-actin monomers, promoting actin polymerization and cytoskeletal reorganization. This drives cell migration, angiogenesis, and wound healing at the cellular level.
Coverage on this site: How Is TB-500 Handled in Research Settings?.